Evidence map›Paper›PMID 34016719›Full record

ArticleLupus science & medicine2021

What are the topics you care about making trials in lupus more effective? Results of an Open Space meeting of international lupus experts.

Johanna Mucke, Marta Alarcon-Riquelme, Jeanette Andersen, Martin Aringer, Stefano Bombardieri, Ralph Brinks, Ricard Cervera, Gamal Chehab, Alain Cornet, Nathalie Costedoat-Chalumeau and 16 more

Abstract read
In one paragraph

Article in Lupus science & medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Johanna MuckePoliclinic and Hiller Research Unit, Heinrich Heine University Düsseldorf, Dusseldorf, Nordrhein-Westfalen, Germany johanna.mucke@med.uni-duesseldorf.de.ORCID 0000-0001-8915-7837
Marta Alarcon-RiquelmeGENYO, Centre for Genomics and Oncological Research, Pfizer/University of Granada/Andalusian Regional Government, Granada, Spain.
Jeanette AndersenLupus Europe, Romford, UK.
Martin AringerDivision of Rheumatology, Department of Medicine III and interdisciplinary University Center for Autoimmune and Rheumatic Entities (UCARE), University Medical Center and Faculty of Medicine Carl Gustav Carus at the TU Dresden, Dresden, Germany.
Stefano BombardieriDepartment of Rheumatology, University of Pisa, Pisa, Italy.
Ralph BrinksPoliclinic and Hiller Research Unit, Heinrich Heine University Düsseldorf, Dusseldorf, Nordrhein-Westfalen, Germany.
Ricard CerveraDepartment of Autoimmune Diseases, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain.
Gamal ChehabPoliclinic and Hiller Research Unit, Heinrich Heine University Düsseldorf, Dusseldorf, Nordrhein-Westfalen, Germany.
Alain CornetLupus Europe, Romford, UK.
Nathalie Costedoat-ChalumeauDepartment of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, Paris, France.
László CzirjákDepartment of Rheumatology and Immunology, University of Pecs, Pecs, Hungary.
Andrea DoriaDivision of Rheumatology, University of Padova, Padova, Italy.ORCID 0000-0003-0548-4983
Rebecca Fischer-BetzPoliclinic and Hiller Research Unit, Heinrich Heine University Düsseldorf, Dusseldorf, Nordrhein-Westfalen, Germany.
Richard A FurieRheumatology, Northwell Health, Great Neck, New York, USA.
Mariele GattoDivision of Rheumatology, University of Padova, Padova, Italy.
Frédéric A HoussiauPôle de pathologies rhumatismales, Université catholique de Louvain, Institut de Recherche Expérimentale et Clinique, Brussels, Belgium.
Luis InesFaculty of Health Sciences, Universidade da Beira Interior, Covilha, Castelo Branco, Portugal.
Matthew H LiangDivision of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, and Section of Rheumatology, VA Boston Healthcare System, West Roxbury, Massachusetts, USA.
Eric MorandSchool of Clinical Sciences at Monash Health, Monash University Faculty of Medicine, Nursing and Health Sciences, Monash Medical Centre Clayton, Clayton, Victoria, Australia.
Marta MoscaDepartment of Rheumatology, University of Pisa, Pisa, Italy.
José María Pego-ReigosaRheumatology Department, University Hospital of Vigo, IRIDIS (Investigation in Rheumatology and Immune-Mediated Diseases)-VIGO Group, Galicia Sur Health Research Institute (IISGS), Vigo, Spain.
Iñigo Rúa-FigueroaRheumatology Department, Doctor Negrín University Hospital of Gran Canaria, Las Palmas de Gran Canaria, Spain.
Guillermo Ruiz-IrastorzaAutoimmune Diseases Research Unit, BioCruces Bizkaia Health Research Institute, Hospital Universitario Cruces, University of the Basque Country, Barakaldo, Spain.
Benjamin TerrierDepartment of Internal Medicine, National Reference Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, Paris, France.
Anne VossDepartment of Rheumatology, Odense University Hospital, University of Southern Denmark, Odense, Syddanmark, Denmark.
Matthias SchneiderPoliclinic and Hiller Research Unit, Heinrich Heine University Düsseldorf, Dusseldorf, Nordrhein-Westfalen, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite promising candidates for new therapeutic options in the treatment of systemic lupus erythematosus (SLE), many clinical trials have failed in the past few years. The disappointing results have been at least partly be attributed to trial designs. With the aim of stimulating new developments in SLE trial design, an international open space meeting was held on occasion of the European Lupus Meeting 2018 in Duesseldorf, Germany about 'What are the topics you care about for making trials in lupus more effective?'. The Open Space is a participant-driven technology, where the discussion topics and schedule are selected during the meeting by all participants and discussion rounds are led by the people attending encouraging active contributions. Eleven topics were selected for further discussion, of which 6 were voted to be more intensively discussed in two consecutive rounds. Major topics were the optimal handling of glucocorticoids in clinical trials, the improvement of outcome measures, reducing or controlling the placebo response and the identification of biomarkers and stratification parameters. Further, the importance of local and international networks was emphasised. By networking, collaborations are facilitated, patient recruitment is more efficient and treatment can be harmonised thus lead to more successful SLE trials. Further discussions are needed to substantiate the results and develop new trial designs.

Indexed as

Lupus Erythematosus, DiscoidLupus Erythematosus, SystemicGermanyGlucocorticoidsHumansOutcome Assessment, Health CareGlucocorticoidshealth carelupus erythematosusoutcome assessmentqualitative researchsystemic

Identifiers

PMID34016719
PMCPMC8141446

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.